ALLAY-HF
Heart Failure with Preserved Ejection Fraction (HFpEF)
Pivotal TrialActive
Key Facts
Indication
Heart Failure with Preserved Ejection Fraction (HFpEF)
Phase
Pivotal Trial
Status
Active
Company
About Alleviant Medical
Alleviant Medical is an innovative, clinical-stage medical device company pioneering a no-implant interatrial shunt therapy for heart failure. Its core technology, the Alleviant System, is a catheter-based device that creates a small, pressure-relieving passage between the heart's atria, aiming to improve symptoms and quality of life for patients who remain symptomatic despite optimal medical therapy. The company is advancing its technology through two pivotal clinical trials and operates as a pre-revenue, private entity backed by venture capital. If successful, Alleviant's implant-free approach could differentiate it in the growing market for heart failure interventional devices.
View full company profileTherapeutic Areas
Other Heart Failure with Preserved Ejection Fraction (HFpEF) Drugs
| Drug | Company | Phase |
|---|---|---|
| Barostim™ | CVRx | Clinical Feasibility |
| MANP | E-Star BioTech | Phase 1/2 |
| PEGylated Pirfenidone | i-Cordis | Pre-clinical |
| VS-041 | Vasa Therapeutics | Phase 1 |
| Neucardin® | Zensun Sci & Tech | Phase 2 |
| SAVM Procedure | Axon Therapies | Phase 2 |
| SRD001 (inferred) | Sardocor | Phase 1 |
| STM-01 | Secretome Therapeutics | Phase 1 |